A Variant of TNFR2-Fc Fusion Protein Exhibits Improved Efficacy in Treating Experimental Rheumatoid Arthritis

Etanercept, a TNF receptor 2-Fc fusion protein, is currently being used for the treatment of rheumatoid arthritis (RA). However, 25% to 38% of patients show no response which is suspected to be partially due to insufficient affinity of this protein to TNFα. By using computational protein design, we found that residue W89 and E92 of TNFR2 were critical for ligand binding. Among several mutants tested, W89Y/E92N displayed 1.49-fold higher neutralizing activity to TNFα, as compared to that of Etanercept. Surface plasmon resonance (SPR) based binding assay revealed that the equilibrium dissociation constant of W89Y/E92N to TNFα was 3.65-fold higher than that of Etanercept. In a rat model of collagen-induced arthritis (CIA), W89Y/E92N showed a significantly better ability than Etanercept in reducing paw swelling and improvement of arthritic joint histopathologically. These data demonstrate that W89Y/E92N is potentially a better candidate with improved efficacy in treating RA and other autoimmune diseases.

[1]  Emanuela Mazzon,et al.  Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. , 2005, Arthritis and rheumatism.

[2]  Simon C Watkins,et al.  Nitric Oxide Protects Cultured Rat Hepatocytes from Tumor Necrosis Factor-α-induced Apoptosis by Inducing Heat Shock Protein 70 Expression* , 1997, The Journal of Biological Chemistry.

[3]  E. Remmers,et al.  Animal models of rheumatoid arthritis and related inflammation , 1999, Current rheumatology reports.

[4]  Philip Rosenstiel,et al.  p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease1 , 2002, The Journal of Immunology.

[5]  H. Seymour,et al.  Anti-TNF agents for rheumatoid arthritis. , 2001, British journal of clinical pharmacology.

[6]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[7]  Xuliang Jiang,et al.  Structure-Expression Relationship of Tumor Necrosis Factor Receptor Mutants That Increase Expression* , 2003, Journal of Biological Chemistry.

[8]  S. Deventer,et al.  Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease , 2002, Gut.

[9]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[10]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[11]  Alan Menter,et al.  Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. , 2003, Clinics in dermatology.

[12]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[13]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[14]  A. Alonso-Ruiz,et al.  Bmc Musculoskeletal Disorders Tumor Necrosis Factor Alpha Drugs in Rheumatoid Arthritis: Systematic Review and Metaanalysis of Efficacy and Safety , 2008 .

[15]  D. Baker,et al.  Computational redesign of protein-protein interaction specificity , 2004, Nature Structural &Molecular Biology.

[16]  I. Weber,et al.  Model complexes of tumor necrosis factor-alpha with receptors R1 and R2. , 1995, Protein engineering.

[17]  John Chan,et al.  Differences in Reactivation of Tuberculosis Induced from Anti-TNF Treatments Are Based on Bioavailability in Granulomatous Tissue , 2007, PLoS Comput. Biol..

[18]  I. Weber,et al.  Crystal structure of TNF-alpha mutant R31D with greater affinity for receptor R1 compared with R2. , 1997, Protein engineering.

[19]  W. Lesslauer,et al.  Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. , 1998, Journal of immunology.

[20]  W. Lesslauer,et al.  Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. , 1998, Journal of immunology.

[21]  V. Rybin,et al.  Computer-aided design of a PDZ domain to recognize new target sequences , 2002, Nature Structural Biology.

[22]  K. Smith,et al.  Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. , 2001, Journal of the American Academy of Dermatology.

[23]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[24]  A G Porter,et al.  Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor beta (lymphotoxin). , 1991, Protein engineering.

[25]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[26]  Philip Rosenstiel,et al.  p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. , 2002, Journal of immunology.

[27]  M. Goldenberg,et al.  Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. , 1999, Clinical therapeutics.

[28]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[29]  S. Ho,et al.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. , 1989, Gene.